Difference between revisions of "Team:CCU Taiwan/Human Practices"

m
m
Line 255: Line 255:
 
                 <br>
 
                 <br>
 
                 <li>Dr. Sugi Guthula (Ph.D. in Chemistry and Biochemistry, expert in applications of nanoplasmonic biosensors)</li>
 
                 <li>Dr. Sugi Guthula (Ph.D. in Chemistry and Biochemistry, expert in applications of nanoplasmonic biosensors)</li>
                 <p>Dr. Guthula suggested we use MHDA (mercaptohexadecanoic acid)/SB-SH (1-(2-sulfosulfanylethylamino)tetradecane) to modify the gold nanoparticles. MHDA has a long-chain hydrocarbon, which forms a monolayer on the gold nanoparticles, and therefore, has a lower tendency for specific absorption. Meanwhile, the EDC/NHS approach still can be applied to the carboxylic group from MHDA for further interaction with peptides. Thus, we decided to modify our gold nanoparticles with MHDA/SB-SH.</p>
+
                 <p>Dr. Guthula suggested we use MHA/SB thiol to modify the gold nanoparticles. MHA has a long-chain hydrocarbon, which forms a monolayer on the gold nanoparticles, and therefore, has a lower tendency for specific absorption. Meanwhile, the EDC/NHS approach still can be applied to the carboxylic group from MHDA for further interaction with peptides. Thus, we decided to modify our gold nanoparticles with MHDA/SB-SH.</p>
 
             </ol>
 
             </ol>
 
             <br>
 
             <br>

Revision as of 14:54, 27 October 2020

Integrated Human Practice